Minimus Spine Signs Initial EU Distribution Deal
Elizabeth Hofheinz, M.P.H., M.Ed. • Mon, December 4th, 2017
Minimus Spine Inc., headquartered in Austin, Texas, has signed its first European distribution agreement and completed its first commercial order.
The agreement was signed with MOSS S.p.A., an Italian company that has been granted exclusive distribution rights for Italy, Germany, Switzerland and the UK.
According to Minimus Spine’s CEO and President David M. Hooper, Ph.D., “We are happy to be working with Franco Papa and his company MOSS. MOSS has a range of novel products tailored for the interventional radiology community and this provides us with key distribution channels in Europe. Our plan is to introduce Triojection to select accounts over the next few months and expand the launch with additional distributors next year.”
Franco Papa, president and CEO of MOSS, added, “We are pleased to be partnering with Minimus in their European commercialization effort. Over the past months, we introduced the Triojection concept to leading physicians at selected European reference centres with the aim of significantly promoting a successful market penetration.”
Dr. Hooper commented to OTW, “The agreement gives Minimus distribution channels in several European countries and enables us to introduce Triojection to a wider group of physicians. To date, we have self-limited the availability of Triojection to our post-market study comparing to discectomy. While we are continuing to enroll that study, we are nearing the completion of enrollment. Now, we are aiming to leverage both our CE Mark and the coming clinical data to build a business around Triojection and the use of ozone in the treatment of herniated discs. Once we start to demonstrate commercial traction in Europe, we should be in position to accelerate our efforts pertaining to the U.S. regulatory pathway.”